

eFigure 1. Response rates over time. Proportions of patients who achieved ≥ 50%, ≥ 75%, and 100% reduction in monthly migraine days (MMD) from baseline for patients in the parent double blind study receiving placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg and for patients receiving erenumab 70/140 mg erenumab in the OLTP.



eFigure 2. Change in MSQ over time. Changes from baseline in mean (A) MSQ-RFR score, (B) MSQ-RFP score, (C) MSQ-EF score are shown for patients on placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg during the double-blind parent study and for all patients on erenumab 70/140 mg during the OLTP. Error bars represent SE. EF, emotional function; MSQ, Migraine-Specific Quality of Life; OLTP, open-label treatment phase; RFP, role function-preventative; RFR, role function-restrictive; SE, standard error.



eFigure 3. Change in MIDAS over time. Changes from baseline in mean (A) MIDAS total score, (B) MIDAS presenteeism, and (C) MIDAS absenteeism are shown for patients on placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg during the double-blind parent study and for all patients on erenumab 70/140 mg during the OLTP. Error bars represent SE. MIDAS, Migraine Disability Assessment; OLTP, open-label treatment phase; SE, standard error.

eTable 1. Exposure-adjusted patient incidence rates of serious adverse events during the open-label treatment phase (per 100 patient-years)

	Erenumab		
	70 mg (N=383) n [r]	140 mg (N=250) n [r]	Total (N=383) n [r]
All serious AEs	30 [4.5]	21 [3.7]	46 [3.8]
Most frequent serious AEs[a]			
Ligament rupture	1 [0.1]	2 [0.3]	3 [0.2]
Osteoarthritis	1 [0.1]	1 [0.1]	2 [0.1]
Uterine leiomyoma	1 [0.1]	1 [0.1]	2 [0.1]
Adjustment disorder	1 [0.1]	1 [0.1]	2 [0.1]
Syncope	2 [0.3]	0 [0.0]	2 [0.1]
Appendicitis	1 [0.1]	2 [0.3]	2 [0.1]
Deep vein thrombosis	1 [0.1]	1 [0.1]	2 [0.1]
Breast cancer	2 [0.3]	0 [0.0]	2 [0.1]

AE, adverse event; n, number of patients reporting at least 1 occurrence of event; r, exposure-adjusted rate per 100 patient-years (n/e×100)

[a]Events with more than one occurrence

eTable 2. Development of anti-erenumab antibodies during the entire study after receiving erenumab 70 mg or 140 mg

	Erenumab 70 mg/140 mg (N=401)
Patients with post-baseline results – N1	400
Baseline results, n (%)	
Binding antibody positive	0 (0.0)
Neutralizing antibody positive	0 (0.0)
Post-baseline results, n (%)	
Binding antibody positive	39 (9.8)
Transient[a]	30 (76.9)
Neutralizing antibody positive	3 (0.8)
Transient[a]	2 (66.7)
First occurrence of binding antibody positive relative to first erenumab 70 mg or 140 mg dose	
Baseline to 3 months	9 (2.3)
> 3 – 6 months	14 (3.5)
> 6 – 9 months	5 (1.3)
> 9 – 12 months	7 (1.8)
> 12 – 18 months	1 (0.3)
> 18 – 24 months	2 (0.5)
> 24 – 36 months	0 (0.0)
> 36 – 48 months	1 (0.3)
> 48 months	0 (0.0)

[a]Negative antibody result at the last time point tested for the patient; percentage based on patients with a post-baseline binding or neutralizing antibody. One patient withdrew from the study so subsequent neutralizing antibody status could not be determined.